Takeda Discontinues Development Of Cholesterol Compound
This article was originally published in PharmAsia News
Executive Summary
Takeda halted development of an investigational drug, TAK-475 (lapaquistat), for the treatment of high cholesterol, based on efficacy and safety data, the company announced March 28.